Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

The decision gives Amgen the upper hand in a hard fought battle for dominance in the new drug class, with both drugs ... a 'reasonably likely' chance that Praluent could be pushed out of the ...

The jury agreed with Regeneron that Amgen unlawfully bundled Repatha with two of its blockbuster anti-inflammatory drugs to persuade pharmacy benefit managers to buy it instead of Praluent.

Regeneron had alleged in a lawsuit that Amgen was purposely excluding Regeneron's anti-inflammatory cholesterol drug Praluent from the marketplace. The pharmaceutical company claimed Amgen bundled ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

Regeneron had alleged in a lawsuit that Amgen was purposely excluding Regeneron's anti-inflammatory cholesterol drug Praluent from the marketplace. The pharmaceutical company claimed Amgen bundled ...